| INTRODUCTION
Obesity has become a major contributor to the global burden of disease in recent years and is associated with co-morbidities, including type 2 diabetes mellitus (T2DM), hypertension, dyslipidaemia, sleep apnea, chronic kidney disease, cardiovascular disease and some cancers. 1, 2 The incidence of obesity has nearly tripled since 1975 according to the World Health Organization. In 2016 it was estimated that 39% of adults were overweight and 13% were obese globally. 3 The main treatments for obesity include lifestyle intervention, pharmacotherapy and bariatric surgery. 4 The estimated annual economic cost of the disease and its associated co-morbidities is over $100 billion in the USA alone, 5 highlighting the need for more effective treatment strategies.
The use of pharmacotherapy in combination with lifestyle intervention (diet and exercise) is recommended for long-term weight management in obese patients with BMI of 30 kg/m 2 and greater or of 27 kg/m 2 and greater in the presence of at least one weight-related comorbid condition such as T2DM or hypertension. 6 Reflecting the unmet medical need for new treatments for obesity, four new drugs have been approved by the FDA and other health authorities since 2012, including lorcaserin, liraglutide, phentermine HCl/topiramate extended release and naltrexone HCl/bupropion HCl. Only liraglutide and naltrexone/bupropion have been approved by the heath authority in the European Union (EMEA). 7 However, most anti-obesity drugs lead to more than 5% weight loss in just a fraction of patients, no cardiovascular benefits have been shown for anti-obesity drugs, and each drug is associated with some safety concerns, 8 leading to limited clinical use. 9 Some agents, such as sibutramine and rimonabant, have been withdrawn from the market because of safety concerns. 10, 11 Not only is the magnitude of the effect of current pharmacotherapy for obesity limited, but weight re-gain following treatment presents an additional hurdle and challenge. 8 There remains a major unmet medical need for novel weight-loss drugs for the treatment of obesity, with improved efficacy and an enhanced safety profile over currently available options.
Selective sodium-glucose co-transporter 2 (SGLT2) inhibitors have been developed as anti-diabetes drugs and lead to a reduction in HbA1c of up to 1%. 12, 13 These agents have also been shown to reduce body weight (1-3 kg reduction) in diabetic patients with and without obesity, 14 with a small magnitude of effect that plateaus by 9 months of treatment. [15] [16] [17] Under physiological conditions, most filtered glucose (80%-90%) is reabsorbed by SGLT2 in the proximal convoluted tubule of the kidney, while the remainder (10%-20%) is reabsorbed by SGLT1 in the S2/S3 segment. The observed urinary glucose excretion of 30%-40% of the filtered glucose load following SGLT2 inhibition is less than the 80%-90% glucose reabsorption via SGLT2 under normal conditions. This discrepancy is probably attributable to increased glucose reabsorption by SGLT1 transporters located in the S3 segment of the proximal tubule, which typically operate at submaximal capacity (10%) under normal physiological conditions. 18 This has been verified by in vivo animal experiments which demonstrated that the SGLT1 transporters can contribute up to 40% of the renal reabsorption of filtered glucose in mice lacking SGLT2. 19 In addition to the kidney, SGLT1 is widely expressed in the small intestine, heart and lungs. [20] [21] [22] 6 As the caloric wasting caused by dual inhibition of SGLT1/2 in the kidneys and gut is through peripheral action, we hypothesize that this may become a promising new approach to reduce body weight.
The objectives of these studies were to assess the effects of licogliflozin on body weight and to investigate the mechanistic biomarkers reflecting the inhibition of SGLT1 in the gut and SGLT1/2 in the kidneys, including glucose, insulin, glucagon and incretin hormones (GLP-1, PYY and GIP).
| METHODS

| Study design and participants
The effects of licogliflozin (150 mg q.d. in six 25 mg tablets or matching placebo for 12 weeks) on body weight in patients with obesity
were assessed in a randomized, double-blind, placebo-controlled, parallel-group study carried out across two centres in the USA.
Patients were instructed to take six tablets with water within 15 minutes of starting the lunch meal (approximately 50% kcal carbohydrates, 30% kcal fat and 20% kcal protein). The effects of licogliflozin on glucose, insulin and incretin hormones (GLP-1, PYY and GIP)
were assessed in a second randomized, double-blind, placebocontrolled study in patients with T2DM, which included two parts: a single-dose crossover study and a 14-day multiple-dose study, with patients enrolled at one centre in the USA. The safety, tolerability and pharmacokinetics (PK) of licogliflozin were also assessed in all studies.
Detailed information on study design is presented online (Appendix S1). 
| Procedures
All eligible participants completed a 28-day screening period, a base- shown online (Appendix S1).
3 | RESULTS
| Patient disposition and characteristics
A total of 130 patients were randomly allocated to treatment with licogliflozin or to placebo in these studies. A total of 88 patients were enrolled in the 12-week treatment study in patients with obesity and 42 patients with T2DM were enrolled in the second study, which included two parts: the 14-day multiple-dose study (30 patients ) and the single-dose crossover study (12 patients Figure S1 and Table S1 ).
| Effect on body weight in patients with obesity
The effect of licogliflozin on body weight was assessed in patients with obesity to determine its effect on weight loss. Figure 1A and Table S2A ).
Body weight was significantly lower in the licogliflozin-treated group than that in the placebo group at all time points starting from Day 7 (all visits; P < 0.001). In the licogliflozin-treated group, a statistically significant difference in weight loss between normoglycaemic and 
| Effects on mechanistic biomarkers (glucose, insulin, incretin hormones) in patients with T2DM
The effects of licogliflozin on glucose and insulin were determined by measuring plasma glucose levels and/or by measuring urinary glucose excretion over 24 hours (Figure 2 ). Plasma glucose excursion (area under the concentration-time curve, AUC 0-4h ) following an OGTT was maximally reduced by 48% with a single dose of licogliflozin 300 mg (morning) as compared to placebo (P < 0.001). This reduction was statistically significant for all doses of licogliflozin relative to placebo (all P < 0.001) ( Figure 2A and Table 1A ). The effect of licogliflozin on glucose excursion was even more evident when inspecting incremental AUC 0-4h levels, which were maximally reduced by 93% following a licogliflozin 300 mg morning dose as compared to placebo (P < 0.001). Following a licogliflozin 300 mg morning dose, insulin levels (AUC 0-4h ) after an OGTT were significantly suppressed by 63% as compared to placebo and incremental insulin AUC 0-4h was reduced by 90% as compared to placebo (both P < 0.001) ( Figure 2B ). Incremental AUC 0-4h revealed an almost complete suppression of insulin following a licogliflozin 300 mg morning dose as compared to placebo (P < 0.001), while no difference in insulin levels was seen after an evening dose of licogliflozin 300 mg as compared to placebo (geometric ratio 11.88; P = 0.673) (Table 1A) . Figure 2D ). In the 14-day study in patients with T2DM, licogliflozin 15 mg q.d. resulted in a placeboadjusted UGE 24 In order to determine the mechanistic effects of SGLT1 inhibition, levels of incretin hormones were assessed following treatment with licogliflozin in patients with T2DM. Administration of 15 mg licogliflozin q.d. for 14 days resulted in a significant increase from baseline in AUC 0-3h for GLP-1 (P < 0.001) ( Figure 3A ) and PYY (P < 0.05) ( Figure 3B ) following an OGTT. Additionally, a 53% reduction in GIP levels from baseline to Day 14 was observed with licogliflozin treatment (P < 0.001) ( Figure 3C and Table 1B ). In the placebo group, no such effects on incretin hormone levels were observed ( Figure S2A-2C ).
| Safety profile of licogliflozin in obese patients and patients with T2DM
The most commonly reported AEs in obese patients and/or patients with T2DM who were treated with licogliflozin were GI-related, including diarrhea reflected by loose stool and/or frequent bowl movements (range, 21%-91%), flatulence (range, 0%-43%), abdominal pain (range, 7%-27%) and headache (range, 0%-20%) ( Table 2 ). Other common AEs included abdominal distension (range, 0%-25%) and nausea (range, 0%-18%). The incidence of AEs was higher in the licogliflozin group than in the placebo group for each study ( Table 2 ). The frequency of gastrointestinal AEs increased with the dose, but most AEs were mild, transient and self-limited. The AEs of diarrhea, mostly loose stool, did not result in clinically meaningful volume depletion or electrolyte abnormalities. The incidence of genitourinary infections across all studies was 3% (one licogliflozin-treated female patient in both the single-dose crossover study and multiple-dose study and two licogliflozin-treated female patients in the 12-week study). Two patients with T2DM in the 14-day study reported AEs of moderate intensity and 14 obese patients (32% receiving licogliflozin 150 mg vs 7% receiving placebo) reported AEs of moderate intensity in the 12-week treatment study. One SAE (perforated appendicitis in one patient treated with licogliflozin 150 mg, which was not suspected to be related to the study drug) was reported in a patient with obesity, which led to study discontinuation.
The mean anion gap in the licogliflozin group was 13.95 mmol/L at baseline and was slightly increased to 14.35 mmol/L after 12 weeks of treatment (12-week study) ( Table S4 ). In the placebo group, the mean anion gap was 13.93 mmol/L at baseline and was slightly decreased to 
| Pharmacokinetics
In patients with T2DM, Cmax and AUCinf of licogliflozin increased in a slightly less than dose-proportional manner across the increasing dose range (2.5-300 mg). Licogliflozin PKs (Cmax and AUC) were similar in dysglycaemic and normoglycaemic obese patients. Detailed PK results are provided online (Appendix S1 and Table S3 ). value of up to 70% inhibition of renal glucose reabsorption, which is higher than that previously reported with SGLT2 inhibitors. 27 Studies in patients with T2DM demonstrated UGE of 69.9 g/day following 2 weeks of treatment with 100 mg dapagliflozin. 28 Compared with the selective SGLT2 inhibitors, the slightly higher UGE 24 observed in our study may be the result of inhibition of SGLT1 along with SGLT2, which would otherwise compensate for the re-absorption of glucose in the absence of SGLT2, or, in the case of selective SGLT2 inhibition, in the kidneys. In support of this hypothesis, sglt1 and sglt2 doubleknockout mice exhibited three times the urinary glucose excretion levels of sglt2-knockout mice. 19 A substantial reduction in post-OGTT glucose excursion levels was also observed in patients with T2DM, along with a reduction in fasting blood glucose. This is plausibly attrib- leading to weight loss. 32 A recent study showed that glucagon increases energy expenditure and decreases adipose tissue expansion in humans. 33 In the current study, 12-week treatment with licogliflozin significantly increased postprandial glucagon levels following glucose challenge, while a conventional pattern was seen in patients who received placebo (glucagon suppression following glucose challenge).
| DISCUSSION
This suggests that a sustained increase in glucagon levels may be a factor contributing to the weight-loss effects of licogliflozin. Treatment with licogliflozin also led to a significant reduction in GIP in patients with T2DM. The potential benefit of this effect is supported by preclinical studies, in which GIP attenuation or GIP receptor gene disruption was associated with contrasting improvements in glucose control, resistance to weight gain and enhanced insulin sensitivity. While improved metabolic outcomes have been reported in clinical studies with GIP-GLP-1-glucagon co-agonists, 36 the extent to which GIP activation or attenuation may impact on obesity remains unclear.
While our biomarker findings with licogliflozin are promising, many of these observations are in small sample sizes of patients and require validation in future larger clinical trials.
In patients with obesity, licogliflozin was associated with a 5.7%
reduction in placebo-adjusted body weight following 12 weeks of treatment. This is in contrast to the 1%-2% reduction in weight that was observed over 12 weeks of treatment with selective SGLT2 inhibition, 37 and it is in line with the clinically meaningful weight loss of >5% (at 12 months) that is required by the FDA for approval of new drugs. 8 sion. 40, 41 In response to intestinal glucose, plasma GIP, glucagon, insulin and SGLT1 were all higher in patients with obesity, compared with lean controls, while GLP-1 was lower. 41 Significant improvements in a number of metabolic parameters were also seen in this study following 12-weeks of treatment, including reduced waist circumference, a reduction in postprandial glucose and insulin and an increase in postprandial glucagon. The weight loss associated with selective SGLT2
inhibitors usually plateaus in the face of continued glucosuria, an effect that is probably the result of increased calorie intake. 42 While the trajectory of weight loss in our study appeared to suggest further weight loss with ongoing treatment, additional studies are required to determine long-term efficacy.
Sotagliflozin was shown to be a potent inhibitor of both SGLT1
and SGLT2 in vitro, with an IC 50 of 36 nmol/L against human SGLT1
and an IC 50 of 1.8 nmol/L against human SGLT2. 26 Multiple clinical studies have been conducted to assess the efficacy and safety of sotagliflozin in patients with diabetes. 26, [43] [44] [45] The effects of sotagliflozin on post-prandial glucose (incremental AUC reduced by <50%) or on UGE24 (~65 g) in patients with diabetes were lesser compared to those seen with licogliflozin in the current study: UGE24 (~100 g);
post-prandial glucose (incremental AUC reduced by >90%). 26, 45 Patients without SGLT1 activity in the gut are known to experience diarrhea as the result of malabsorption of glucose and galactose. 22 The low incidence of diarrheal adverse events (8.5% at the highest dose of 400 mg q.d. tested in human vs 6.7% in placebo group) associated with sotagliflozin is of particular interest, 45 suggesting that SGLT1 activity may not be blocked completely by sotagliflozin in the clinical setting, even at the highest dose tested (400 mg q.d.). Further studies would be required to confirm these indirect comparisons.
In this study, single doses of licogliflozin up to 300 mg and multiple doses up to 150 mg were safe and generally well tolerated in patients with T2DM and in patients with obesity. A higher incidence of diarrhea, reflected by frequent bowel movements and/or loose stool, was reported at higher doses of licogliflozin. However, no faecal Five-period crossover single-dose study in patients with T2DM These results provide mechanistic evidence that higher doses of licogliflozin could completely inhibit the SGLT1 activity in the gut, similar to that observed in patients lacking SGLT1 activity. 22 Mycotic infections are the most common AEs associated with SGLT2 inhibitors, with other AEs, including urinary tract infections, volume depletion, changes in electrolyte balance, elevated ketones associated with diabetic ketoacidosis, fractures and amputations. 46 The incidence of genitourinary infections across all studies was 3%, which was similar to that reported in studies with SGLT2 inhibitors. [47] [48] [49] No AEs related to ketosis or metabolic acidosis were reported in the clinical studies with licogliflozin, although a slightly higher incidence of positive urine dipstick ketone bodies and slightly higher anion gap, as compared to baseline, were reported. Longer and larger clinical trials are needed, to determine whether ketoacidosis is a safety liability associated with licogliflozin. In addition, no significant change in bone turnover markers or in urinary volume was observed. Finally, there were no reports of amputations, bone loss/fractures or acute kidney failure, which are among the safety concerns with SGLT2
inhibitors. Longer and larger trials are required to properly assess the long-term safety risks associated with licogliflozin.
There are some limitations to this study which need to be addressed. The short duration of up to 12 weeks provided limited information on long-term weight-loss and whether a plateau was reached, and/or on the long-term safety risks associated with licogliflozin. As this is a first-in-human and proof-of-concept clinical study, larger and longer trials are therefore required to confirm these preliminary findings. Additional studies will provide information on the long-term safety and efficacy of licogliflozin on body weight, and the potential beneficial effects in reducing cardiovascular risk.
In conclusion, SGLT1/2 inhibition with licogliflozin blocked glucose and insulin rise after glucose challenge, and this resulted in significant weight loss and desirable changes in several metabolic hormones (increased GLP-1, PYY and glucagon, and reduced GIP, glucose and insulin). The effects of SGLT1 inhibition in the gut were indicated by changes in gut incretin hormone levels following treatment (GLP-1, GIP-1 and PYY). As a safe and effective oral therapy, licogliflozin may be an attractive strategy for treatment of obesity. 
